Related Experiment Videos
Docetaxel (Taxotere) in combination: a step forward
H A Burris1, S Fields, N Peacock
1Hematology/Oncology Service Drug Development Program, Brooke Army Medical Center, Ft Sam Houston, TX, USA.
Seminars in Oncology
|December 1, 1995
Summary
Docetaxel, a chemotherapy drug, shows promise in combination therapies for various cancers. Combinations with drugs like 5-fluorouracil and doxorubicin demonstrate significant antitumor activity and acceptable toxicity profiles.
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Docetaxel is a hemisynthetic derivative of European yew, inhibiting tubulin depolymerization and promoting microtubule aggregation, leading to cell death.
- Single-agent chemotherapy is often insufficient for curative outcomes, necessitating combination regimens to improve tumor reduction and survival.
- Preclinical studies indicate synergistic effects of docetaxel with several chemotherapeutic agents, with manageable toxicity profiles.
Purpose of the Study:
- To evaluate the efficacy and safety of docetaxel in combination regimens for various cancer types.
- To explore the potential of docetaxel combinations in improving treatment outcomes compared to single-agent therapies.
- To identify optimal combination partners and dosing for docetaxel-based chemotherapy.
Main Methods:
- Review of preclinical studies assessing docetaxel synergism with agents like vinorelbine, etoposide, cyclophosphamide, 5-fluorouracil, and methotrexate.
- Analysis of clinical trial data (Phase I and II) evaluating docetaxel combinations in solid tumors, metastatic breast cancer, and non-small cell lung cancer.
- Assessment of dose-limiting toxicities and overall safety profiles of various docetaxel combination regimens.
Main Results:
- Docetaxel combinations showed synergistic activity in preclinical models with manageable toxicity.
- Phase I trials indicated activity of docetaxel/5-fluorouracil in refractory solid tumors with manageable neutropenia.
- Docetaxel/doxorubicin demonstrated high response rates in metastatic breast cancer with acceptable toxicity.
- Docetaxel/cyclophosphamide showed partial responses in heavily pretreated breast cancer patients.
- Docetaxel/vinorelbine yielded responses in metastatic breast cancer with dose-limiting toxicity at higher vinorelbine doses.
- Docetaxel/cisplatin showed promising activity and acceptable toxicity in non-small cell lung cancer.
Conclusions:
- Docetaxel-based combination chemotherapy demonstrates significant potential in improving antitumor activity for various cancers.
- Combinations with drugs like doxorubicin, 5-fluorouracil, and cisplatin appear particularly promising for metastatic breast cancer and non-small cell lung cancer.
- Further clinical trials are warranted to optimize docetaxel combination and sequential regimens, especially in metastatic breast cancer and non-small cell lung cancer.